Veidlapa Nr. M-3 (8)
Study Course Description
Myeloproliferative Oncohaematological Diseases
Course Code
RHE_061
Branch of Science
Clinical medicine
ECTS
7.00
Target Audience
Medicine
LQF
Level 8
Study Course Implementer
Course Supervisor
Sandra Lejniece
Residency Speciality
Speciality
Hematologist
Supervisor of Medical Speciality
Sandra Lejniece
Contacts
-
About Study Course
Objective
To ensure acquisition and improvement of theoretical knowledge and practical skills in myeloproliferative oncohaematological diseases in accordance with the requirements of the haematology specialty in order to prepare the doctor for certification in the haematology specialty.
Learning Outcomes
Knowledge
1.- Will know about myeloproliferative diseases; - Will know about chronic myeloid leukaemia, evaluation of treatment results; - Will know about polycythaemia vera; - Will know about myelofibrosis; - Will know about essential thrombocythemia; - Will know about chronic eosinophilic leukemia; - Will know about myeloproliferative diseases with basophilia.
Skills
1.- Will be able to diagnose and treat patients with myeloproliferative diseases.
Competences
1.Diagnosis and treatment of patients with myeloproliferative diseases.
Assessment
Individual work
|
Title
|
% from total grade
|
Grade
|
|---|---|---|
|
1.
Individual work |
-
|
-
|
|
1. Independently studies the literature related to the course topics;
2. Independently prepares for seminars;
3. Independently collects disease anamnesis data, objectively examines the patient, formulates a preliminary diagnosis, which is discussed with the lecturer;
4. Gets acquainted with and analyses medical documentation;
5. Completes medical documentation;
6. Independently follows the instructions of the certified specialist.
|
||
Examination
|
Title
|
% from total grade
|
Grade
|
|---|---|---|
|
1.
Examination |
-
|
-
|
|
Mandatory attendance of seminars (100%) and performance of practical work (100%) in each study course.
|
||
Study Course Theme Plan
FULL-TIME
Part 1
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Characterisation of myeloproliferative diseases. Chronic myeloid leukaemia - pathogenesis, causes, clinic, laboratory diagnosis, stage classification, diagnostic criteria, differential diagnosis, therapy. Evaluation of treatment results - haematological, cytogenetic and molecular remission, indications for allogeneic stem cell transplantation, prognosis.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Polycythaemia vera - pathogenesis, causes, clinic, laboratory diagnosis, stage classification, diagnostic criteria, differential diagnosis, therapy. Evaluation of treatment results, evaluation of thrombosis risk factors. Therapeutic phlebotomy.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Myelofibrosis - pathogenesis, causes, clinic, laboratory diagnosis, stage classification, diagnostic criteria, differential diagnosis, therapy. Evaluation of treatment results, evaluation of thrombosis risk factors.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Essential thrombocythemia - pathogenesis, causes, clinic, laboratory diagnosis, stage classification, diagnostic criteria, differential diagnosis, therapy. Evaluation of treatment results, evaluation of thrombosis risk factors.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Chronic eosinophilic leukemia - clinical and laboratory characterisation, principles of therapy. Myeloproliferative diseases with eosinophilia, various cytogenetic changes.
|
-
Seminar
|
Modality
|
Location
|
|
|---|---|---|
|
-
|
-
|
Topics
|
Myeloproliferative diseases with basophilia, their clinical and laboratory characterisation. Mastocytosis.
|
Total ECTS (Creditpoints):
7.00
Number of Residency Seminars:
6
Length (weeks):
5
Final Examination:
Residency exam (Theory and practice)
Bibliography
Required Reading
1.
Hochhaus, M. Baccarani, R. T. Silver, C. Schiffer, J. F. Apperley, F. Cervantes et al. European LeukemiaNet 2020 recommendations for treatment chronic myeloid leukemia. Leukemia, 2020, 34: 966-984.
2.
Sokal J., Cox E., Baccarani M., et al. Prognostic discrimination in “goodrisk” chronic granulocytic leukemia. Blood 1984; 63:789–799.
3.
Hasford J., Pfirrmann M., Hehlmann R., et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90:850–858.
4.
Marin D., Ibrahim A. R., Goldman J. M. European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. J Clin Oncol 2011;29:3944–3945.
5.
Geelen I. G. P., Sandin F., Thielen N., Janssen J., Hoogendoorm M., Visser O. et al. Validation of the EUTOS long-term survival score in a recent independent cohort of “real world”CML patients. Leukemia. 2018; 32:2299-2303.
6.
Hochhaus A., Dreyling M. On behalf of the ESMO Guidelines Working Group. Chronic myelogenous leukemia: ESMO Clinical Recommendations for the diagnosis, treatment and follow-up. Annals of Oncology 19 (Supplement 2): ii63–ii64, 2008 clinical recommendations doi:10.1093/annonc/mdn091
7.
Cross N. C., White H. E., Muller M. C., Saglio G., Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012; 26:2172–2175.
8.
Soverini S., Hochhaus A., et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.Blood, 2011; 118: 1208-1215.
9.
Radich J. P., Deininger M., Abboud C. N., et al. Chronic Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Myeloid Compr Canc Netw. 2018 Sep;16(9):1108-1135.
10.
Passweg J. R., Walker I., Sobocinski K. A., et al. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004; 125: 613–620.
11.
Gratwohl A., Brand R., Apperley J., Crawley C., et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513–521.
12.
Tefferi et al. Polycytthemia vera treatment algorithm. Blood Cancer Journal 2018; 8:3-7.
13.
Benites B. D., Lima C. S., Lorand-Metze I., et al. Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome. Clinics (Sao Paulo). 2013; 68(3):339-43. PMID: 23644853
14.
NCCN clinical Practice Guidelins in Oncology. Myeloproliferative Neoplasms. Version 2. 2018.
15.
Passamonti F., Mora B., Barraco D., Maffioli M.. Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis. Curr Hematol Malig Rep. 2018 Jun;13(3):173-182. doi: 10.1007/s11899-018-0453-y. PMID: 29713873.
Additional Reading
1.
Passamonti F., Giorgino T., Mora B., et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31. PMID: 28561069
2.
Heim D., Ebnöther M., Favre G. Chronische Myeloische Leukämie – Update 2020 [Chronic myeloid leukemia - update 2020]. Ther Umsch. 2019;76(9):503-509. German. doi: 10.1024/0040-5930/a001124. PMID: 32157969.
3.
Zhou T., Medeiros L. J., Hu S. Chronic Myeloid Leukemia: Beyond BCR-ABL1. Curr Hematol Malig Rep. 2018 Dec;13(6):435-445. doi: 10.1007/s11899-018-0474-6. PMID: 30370478.
4.
Zhou H., Xu R. Leukemia stem cells: the root of chronic myeloid leukemia. Protein Cell. 2015 Jun;6(6):403-12. doi: 10.1007/s13238-015-0143-7. Epub 2015 Mar 10. PMID: 25749979; PMCID: PMC4444810.
5.
Hijiya N., Suttorp M. How I treat chronic myeloid leukemia in children and adolescents. Blood. 2019 May 30;133(22):2374-2384. doi: 10.1182/blood.2018882233. Epub 2019 Mar 27. PMID: 30917954.
6.
Bennour A., Saad A., Sennana H. Chronic myeloid leukemia: Relevance of cytogenetic and molecular assays. Crit Rev Oncol Hematol. 2016 Jan;97:263-74. doi: 10.1016/j.critrevonc.2015.08.020. Epub 2015 Aug 29. PMID: 26412717.
7.
Shanmuganathan N., Hiwase D. K., Ross D. M. Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome. Leuk Lymphoma. 2017 Dec;58(12):2799-2810. doi: 10.1080/10428194.2017.1312377. Epub 2017 May 9. PMID: 28482729.
8.
Minami Y. Guest editorial: chronic myeloid leukemia. Int J Hematol. 2018 Oct; 108(4):353-354. doi: 10.1007/s12185-018-2521-4. Epub 2018 Aug 28. PMID: 30155590.
9.
Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021 Jan;96(1):145-162. doi: 10.1002/ajh.26050. Epub 2020 Dec 2. PMID: 33197049.
10.
Yoon S. Y., Won J. H. The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms. Blood Res. 2021 Apr 30;56(S1):S44-S50. doi: 10.5045/br.2021.2020334. PMID: 33935035; PMCID: PMC8093996.
11.
Marcellino B., El Jamal S. M., Mascarenhas J. O. Distinguishing autoimmune myelofibrosis from primary myelofibrosis. Clin Adv Hematol Oncol. 2018 Sep;16(9):619-626. PMID: 30256778.
12.
Gilani J. A., Ashfaq M. A., Mansoor A. E., et al. Overview of the Mutational Landscape in Primary Myelofibrosis and Advances in Novel Therapeutics. Asian Pac J Cancer Prev. 2019 Jun 1;20(6):1691-1699. doi: 10.31557/APJCP.2019.20.6.1691. PMID: 31244289; PMCID: PMC7021616.
13.
Parra Salinas I., Recasens Flores V., Montañés M. Á., García-Erce J. A. Therapeutic erythroapheresis: Experience in patients with polycythemia vera and secondary erythrocytosis. Med Clin (Barc). 2020 Jan 10;154(1):16-19. English, Spanish. doi: 10.1016/j.medcli.2018.12.016. Epub 2019 Feb 19. PMID: 30795904.
14.
Faustino F. G., Teixeira R., et al. Acute Myocardial Infarction as First Onset of Polycythemia Vera. Arq Bras Cardiol. 2020 Apr;114(4 Suppl 1):27-30. English, Portuguese. doi: 10.36660/abc.20190104. Epub 2020 May 18. PMID: 32428108.